研究单位：[1]Xiamen Amoytop Biotech Co., Ltd[2]Tongji Hospital, Huazhong University of Science & Technology 华中科技大学同济医学院附属同济医院[3]Peking University First Hospital[4]Peking University People's Hosopital[5]Fuzhou Infectious Disease Hospital
研究目的：
This study is a multi-center, randomized, prospective open-label study to assess the efficacy and safety of combination of peginterferon alfa-2b (40kD, Y-shape) and GM-CSF in interferon-naïve chronic hepatitis B patients with HBeAg positive. Patients were randomized to one of the 2 groups to receive different antiviral treatment.
